Treatment of Smith-Lemli-Opitz syndrome: Results of a multicenter trial

Mira Irons*, Ellen R. Elias, Diane Abuelo, Marilyn J. Bull, Carol L. Greene, Virginia P. Johnson, Laura Keppen, Carolyn Schanen, G. Stephen Tint, Gerald Salen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

127 Scopus citations


Patients with the RSH or Smith-Lemli-Opitz syndrome (SLOS) have an inborn error of cholesterol biosynthesis which results in a deficiency of cholesterol and an elevation of the cholesterol precursor, 7- dehydrocholesterol. A treatment protocol consisting of administration of cholesterol ± bile acids was initiated in an attempt to correct the biochemical abnormalities seen. Fourteen patients (8 female, 6 male: ages 2 months to 15 years) have now been treated for 6-15 months. Three patients received cholesterol alone, while 11 patients received cholesterol and one or more bile acids. Biochemical improvement in sterol levels and in the ratio of cholesterol to total sterols was noted in all patients. The most marked improvement was noted in patients presenting with initial cholesterol levels <40 mg/dl. No toxicity was observed. Clinical improvement in growth and neurodevelopmental status was also observed.

Original languageEnglish (US)
Pages (from-to)311-314
Number of pages4
JournalAmerican Journal of Medical Genetics
Issue number3
StatePublished - 1997
Externally publishedYes


  • Smith-Lemli-Opitz syndrome
  • cholesterol
  • sterol metabolism bile acids
  • treatment

ASJC Scopus subject areas

  • Genetics(clinical)


Dive into the research topics of 'Treatment of Smith-Lemli-Opitz syndrome: Results of a multicenter trial'. Together they form a unique fingerprint.

Cite this